SCHEMBL14137635

SCHEMBL14137635

CCOC(=O)C1C2CCC(C2)C1NC

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPM1B O75688 1/20 0.41
PTPN1 P18031 1/20 0.41
PPP1CC P36873 1/20 0.41
ALDH1A1 P00352 6/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
EPHX2 P34913 1/20 0.35
MAPT P10636 1/20 0.34
KCNH2 Q12809 1/20 0.34
RORC P51449 1/20 0.34
TSHR P16473 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14038149 1.00 PPM1B (0.41) PPM1BPTPN1PPP1CCALDH1A1MEN1
SCHEMBL12992688 1.00 PPM1B (0.41) PPM1BPTPN1PPP1CCALDH1A1MEN1
SCHEMBL9605862 0.86 PPM1B (0.52) PPM1BPTPN1PPP1CCALDH1A1MEN1
SCHEMBL14189733 0.86 PPM1B (0.52) PPM1BPTPN1PPP1CCALDH1A1MEN1
SCHEMBL10050521 0.86 PPM1B (0.52) PPM1BPTPN1PPP1CCALDH1A1MEN1
SCHEMBL8400471 0.86 PPM1B (0.52) PPM1BPTPN1PPP1CCALDH1A1MEN1
SCHEMBL14189734 0.86 PPM1B (0.52) PPM1BPTPN1PPP1CCALDH1A1MEN1
SCHEMBL6128867 0.85 MEN1 (0.43) PPM1BPTPN1PPP1CCALDH1A1MEN1
SCHEMBL14034644 0.85 MEN1 (0.43) PPM1BPTPN1PPP1CCALDH1A1MEN1
SCHEMBL392906 0.81 ALDH1A1 (0.40) PPM1BPTPN1PPP1CCALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012170536-A1 [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID ANADYS PHARMACEUTICALS, INC. (US) 2012-12-13 WO disclosed
US-20120302744-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2012-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302744-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS DPYD, NQO1, MT-ND5 PPM1B 1509/4885PTPN1 1869/4885PPP1CC 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.